FDA Drug Recalls
70 recalls · Class I, newest first
Class I · High risk Ongoing Jul 11, 2024
Reason Labeling: Missing Label - some bottles are missing the the manufacturers label that includes the drug facts information.
Class I · High risk Terminated Jul 10, 2024
Reason Labeling: Label Error on Declared Strength; Some cartons were incorrectly labeled as 0.125 mg instead of 0.25 mg. The blister strips inside the…
Class I · High risk Ongoing Jul 8, 2024
Reason Labeling: Label Mix-up: a bag of Dexmedetomidine HCl in 0.9% Sodium Chloride Injection was found inside an overwrap labeled Acetaminophen Injection…
Class I · High risk Ongoing Jun 25, 2024
Reason Failed Dissolution Specifications
Class I · High risk Terminated Jun 21, 2024
Reason Labeling: Label Mix-Up: Some bottles of Acetaminophen Extra Strength 500 mg tablets were incorrectly labeled with the drug facts label for Aspirin 81…
Class I · High risk Terminated Jun 5, 2024
Reason Microbial Contamination of Non-Sterile Products: multiple Bacillus species organisms
Class I · High risk Ongoing May 30, 2024
Reason Failed Dissolution Specifications
Class I · High risk Ongoing May 30, 2024
Reason Failed Dissolution Specifications
Class I · High risk Ongoing May 28, 2024
Reason Presence of Particulate Matter: Presence of particulate matter from the stopper in the drug product.
Class I · High risk Ongoing May 28, 2024
Reason Presence of Particulate Matter: Presence of particulate matter from the stopper in the drug product.
Class I · High risk Ongoing May 24, 2024
Reason Microbial Contamination of Non-Sterile Products: Presence of Aspergillus Sydowii (Mold)
Class I · High risk Completed Apr 29, 2024
Reason Labeling: Label mix-up - ephedrine syringes mislabeled as phenylephrine.
Class I · High risk Terminated Apr 22, 2024
Reason Marketed Without An Approved NDA/ANDA
Class I · High risk Ongoing Apr 20, 2024
Reason Labeling: Label Mix-up - product labeled as tirzepatide contains testosterone cypionate
Class I · High risk Ongoing Apr 8, 2024
Reason Sub-potent Drug; powder discoloration associated with decreased potency
Class I · High risk Ongoing Apr 8, 2024
Reason Sub-potent Drug; powder discoloration associated with decreased potency
Class I · High risk Terminated Mar 28, 2024
Reason Microbial contamination of a non-sterile product: potential Bacillus cereus contamination.
Class I · High risk Ongoing Mar 23, 2024
Reason Chemical Contamination: Product manufactured with ethanol API that contains methanol
Class I · High risk Ongoing Mar 23, 2024
Reason Chemical Contamination: Product manufactured with ethanol API that contains methanol
Class I · High risk Terminated Mar 21, 2024
Reason Superpotent Drug: Due to overfilling of drug powder
Class I · High risk Ongoing Mar 19, 2024
Reason Marketed without an approved NDA/ANDA: Products found to contain undeclared sildenafil and/or tadalafil.
Class I · High risk Ongoing Mar 19, 2024
Reason Marketed without an approved NDA/ANDA: Products found to contain undeclared sildenafil and/or tadalafil.
Class I · High risk Ongoing Mar 19, 2024
Reason Marketed without an approved NDA/ANDA: Products found to contain undeclared sildenafil and/or tadalafil.
Class I · High risk Ongoing Mar 19, 2024
Reason Marketed without an approved NDA/ANDA: Products found to contain undeclared sildenafil and/or tadalafil.
Class I · High risk Ongoing Mar 19, 2024
Reason Marketed without an approved NDA/ANDA: Products found to contain undeclared sildenafil and/or tadalafil.